RxDoctor Payments Data

Gerald Volcheck, MD

Allergy & Immunology · Rochester, MNNPI 1326028812

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, GSK. That places this record below the midpoint for allergy & immunology clinicians in MN, where the typical reported total is $213.

$15in general payments, 2019–2025

Across 1 payment — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$15
$243,175in research payments, 2019–2025

Across 21 payments — averaging $11,580 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$243K

What the payments were for

  • Food & beverage$15100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK1$15

How this compares

$15 in reported general payments places this provider in the 10th percentile of 57 allergy & immunology providers in Minnesota.

See all allergy & immunology providers in Minnesota

Medicare billing

Part B allowed, 2024
$33,944
Medicare patients
208
Services billed
2,330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab13$47,630
Breo ElliptaFluticasone/Vilanterol26$14,620
Advair HfaFluticasone Propion/Salmeterol28$11,659
Fluticasone Propionate HfaFluticasone Propionate27$8,362
DuleraMometasone/Formoterol15$8,041
Incruse ElliptaUmeclidinium Bromide13$4,607
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$3,998
Montelukast Sodium95$1,201
Ventolin HfaAlbuterol Sulfate17$958
Albuterol Sulfate HfaAlbuterol Sulfate27$843
Sodium ChlorideSodium Chloride Irrig Solution12$350
Prednisone46$287
Famotidine12$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Breo Ellipta, Incruse Ellipta$15$66,85652 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 57 allergy & immunology providers in Minnesota.

Other allergy & immunology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →